AbbVie Inc (ABBV)vsHeron Therapeuti (HRTX)
ABBV
AbbVie Inc
$261.07
+3.99%
HEALTHCARE · Cap: $447.62B
HRTX
Heron Therapeuti
$0.44
-11.60%
HEALTHCARE · Cap: $80.78M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 41581% more annual revenue ($62.82B vs $150.71M). ABBV leads profitability with a 5.8% profit margin vs -20.5%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
HRTX
Avoid27
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-78.1%
Fair Value
$146.57
Current Price
$261.07
$114.50 premium
Intrinsic value data unavailable for HRTX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Generating 3.6B in free cash flow
No standout strengths identified
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
Trading at 11.0x book value
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -338.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.41 suggests the stock is reasonably priced for its growth.
Bull Case : HRTX
HRTX has a balanced fundamental profile.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 123.6x leaves little room for execution misses.
Bear Case : HRTX
The primary concerns for HRTX are Price/Book, EPS Growth, Market Cap. Debt-to-equity of 15.50 is elevated, increasing financial risk.
Key Dynamics to Monitor
ABBV profiles as a value stock while HRTX is a turnaround play — different risk/reward profiles.
HRTX carries more volatility with a beta of 1.57 — expect wider price swings.
ABBV is growing revenue faster at 12.4% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 27/100) and 12.4% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Heron Therapeuti
HEALTHCARE · BIOTECHNOLOGY · USA
Heron Therapeutics, Inc., a biotechnology company, is dedicated to developing treatments to address unmet medical needs. The company is headquartered in San Diego, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?